乐卡地平相关化合物1 | 23808-47-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 乐卡地平相关化合物1
• 英文名称: 3,3-diphenylpropyl 4-methylbenzenesulfonate
• CAS: 23808-47-1
• 化学式: C₂₂H₂₂O₃S
• 分子量: 366.481
• InChiKey: NENUCJVGUPDXPC-UHFFFAOYSA-N

物化性质

• 熔点：
  115-120°C
• 溶解度：
  可溶于氯仿（轻微）、己烷（轻微、加热）

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  乐卡地平相关化合物1 在 氢氧化钾 作用下， 以 乙醇 、 水 为溶剂， 反应 18.0h， 生成 4-(3,3-diphenyl-1-propyl)piperazine
  参考文献：
  名称：

  New 1,3-dioxolane and 1,3-dioxane derivatives as effective modulators to overcome multidrug resistance

  摘要：

  Multidrug resistance (MDR) to antitumor agents represents a major obstacle to a successful chemotherapy of cancer. Overexpression of P-glycoprotein (p-gp) seems to be the major factor responsible for MDR. A large number of chemically unrelated compounds are known to interact with p-gp resulting in a decreasing resistance. In our efforts related to structure-activity studies of new potential MDR reversal agents we synthesized a series of compounds that differ in the aromatic core structure, the linker, and the basic moiety. For our search of new aromatic core structures we synthesized novel 2,2-diphenyl-1,3-dioxolane, 2,2- diphenyl-1,3-dioxane, and 4,5-diphenyl-1,3-dioxolane derivatives. A range of lipophilic linker structures and protonable basic moieties were synthesized and investigated to optimize the structure of the potential MDR-modulators. The compounds were tested in vitro using human Caco-2 cells. Both the cytotoxicity of the synthons and their ability to resensitize the cells were determined with a MTT assay. The results show that at low concentration various substances reverse tumor cell MDR. Some of the new structures show better effects than established modulators like trifluoperazine. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.01.024
• 作为产物：
  描述：

  3,3-二苯基丙酸 在 lithium aluminium tetrahydride 、 硫酸 、 三乙胺 作用下， 以 乙醚 、 氯仿 为溶剂， 反应 29.0h， 生成 乐卡地平相关化合物1
  参考文献：
  名称：

  New 1,3-dioxolane and 1,3-dioxane derivatives as effective modulators to overcome multidrug resistance

  摘要：

  Multidrug resistance (MDR) to antitumor agents represents a major obstacle to a successful chemotherapy of cancer. Overexpression of P-glycoprotein (p-gp) seems to be the major factor responsible for MDR. A large number of chemically unrelated compounds are known to interact with p-gp resulting in a decreasing resistance. In our efforts related to structure-activity studies of new potential MDR reversal agents we synthesized a series of compounds that differ in the aromatic core structure, the linker, and the basic moiety. For our search of new aromatic core structures we synthesized novel 2,2-diphenyl-1,3-dioxolane, 2,2- diphenyl-1,3-dioxane, and 4,5-diphenyl-1,3-dioxolane derivatives. A range of lipophilic linker structures and protonable basic moieties were synthesized and investigated to optimize the structure of the potential MDR-modulators. The compounds were tested in vitro using human Caco-2 cells. Both the cytotoxicity of the synthons and their ability to resensitize the cells were determined with a MTT assay. The results show that at low concentration various substances reverse tumor cell MDR. Some of the new structures show better effects than established modulators like trifluoperazine. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.01.024

文献信息

• [EN] FENDILINE DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS DE FENDILINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV TEXAS

  公开号：WO2014031755A1

  公开（公告）日：2014-02-27

  Disclosed herein are novel derivatives of fendiline, including compounds of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising these derivative compounds. Methods and intermediates useful for making the derivatives, and methods of using the derivatives, for example, for the inhibition of K-Ras plasma membrane localization, and compositions thereof, including for the treatment of cancer, are also provided.

  本发明公开了芬地林的新的衍生物，包括具有以下通式的化合物：其中变量在本发明中定义。还提供了包含这些衍生物化合物的药物组合物、试剂盒和制品。本发明还提供了用于制造衍生物的方法和中间体，以及使用衍生物的方法，例如，用于抑制K-Ras质膜定位，以及用于治疗癌症的此类组合物。
• Nickel-catalyzed reductive monofluoroakylation of alkyl tosylate with bromofluoromethane to primary alkyl fluoride
  作者：Ru Cui、Jie Sheng、Bing-Bing Wu、Duo-Duo Hu、Hong-Qian Zheng、Xi-Sheng Wang

  DOI：10.1039/d1cc02837e

  日期：——

  A nickel-catalysed direct terminal monofluoromethlyation between alkyl tosylates and a low-cost, industrial raw material bromofluoromethane has been developed. This transformation has demonstrated high efficiency, mild conditions, and good functional-group compatibility. The key to success of this transformation lies in the ligand and mild base selection, ensuring the generation of various terminal

  已开发出在甲苯磺酸烷基酯和低成本工业原料溴氟甲烷之间的镍催化直接末端单氟甲基化。这种转化具有高效、温和的条件和良好的官能团兼容性。这种转化成功的关键在于配体和温和的碱基选择，确保产生各种末端单氟甲基化产物。
• Iron-Catalyzed Regioselective Transfer Hydrogenative Couplings of Unactivated Aldehydes with Simple Alkenes
  作者：Yan-Long Zheng、Yan-Yao Liu、Yi-Mei Wu、Yin-Xia Wang、Yu-Tong Lin、Mengchun Ye

  DOI：10.1002/anie.201602130

  日期：2016.5.17

  An FeBr3‐catalyzed reductive coupling of various aldehydes with alkenes that proceeds through a direct hydride transfer pathway has been developed. With iPrOH as the hydrogen donor under mild conditions, previously challenging coupling reactions of unactivated alkyl and aryl aldehydes with simple alkenes, such as styrene derivatives and α‐olefins, proceeded smoothly to furnish a diverse range of functionalized

  已经开发出FeBr 3催化的通过直接氢化物转移途径进行的各种醛与烯烃的还原偶联。以i PrOH作为氢供体在温和的条件下，以前挑战性的未活化烷基和芳基醛与简单烯烃（如苯乙烯衍生物和α-烯烃）的偶合反应顺利进行，以提供具有完全线性区域选择性的各种官能化醇。
• [EN] PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS<br/>[FR] PRODUIT PHARMACEUTIQUE POUR LE TRAITEMENT DE TROUBLES NEUROLOGIQUES ET NEUROPSYCHIATRIQUES
  申请人：TROPHIX PHARMACEUTICALS, INC.

  公开号：WO1997045115A1

  公开（公告）日：1997-12-04

  (EN) The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.(FR) Cette invention concerne un produit pharmaceutique destiné au traitement de troubles neurologiques ou neuropsychiatriques. Ledit produit pharmaceutique comprend un composé ayant la formule (I) ou un sel pharmaceutiquement acceptable dudit composé.

  该发明提供了一种用于治疗神经和神经精神障碍的药物，包括公式(I)的化合物或其药学上可接受的盐。
• Pharmaceutical for treatment of neurological and neuropsychiatric disorders
  申请人：——

  公开号：US20010012857A1

  公开（公告）日：2001-08-09

  The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: 1 or a pharmaceutically acceptable salt thereof.

  该发明提供了一种用于治疗神经和神经精神障碍的药物，包括式1的化合物或其药学上可接受的盐。